March 8, 2017 / 1:36 PM / 4 months ago

BRIEF-Abeona Therapeutics receives orphan drug designation in the European Union for EB-101

1 Min Read

March 8 (Reuters) - Abeona Therapeutics Inc

* Abeona Therapeutics receives orphan drug designation in the European Union for EB-101 gene therapy clinical trial for epidermolysis bullosa

* Abeona Therapeutics - EB-101 gene therapy has demonstrated promising efficacy and safety in ongoing phase 1/2 clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below